董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kevin E. Lofton | 男 | Chair of the Board and Director | 71 | 52.24万美元 | 未持股 | 2026-10-09 |
| Glenn Eisenberg | 男 | Director | 65 | 26.29万美元 | 未持股 | 2026-10-09 |
| Matthew R. Walter | 男 | Director | 48 | 未披露 | 未持股 | 2026-10-09 |
| Robert A. Hopkins | 男 | Director | 58 | 未披露 | 未持股 | 2026-10-09 |
| Laura Mauri | 女 | Director | 56 | 未披露 | 未持股 | 2026-10-09 |
| Que Dallara | 女 | Chief Executive Officer and Director | 52 | 843.02万美元 | 3.43 | 2026-10-09 |
| Linnea Burman | 女 | Director | 52 | 未披露 | 未持股 | 2026-10-09 |
| Scott Cundy | 男 | Director | 56 | 未披露 | 未持股 | 2026-10-09 |
| Timothy A. Wicks | 男 | Director | 61 | 26.39万美元 | 未持股 | 2026-10-09 |
| D. Keith Grossman | 男 | Director | 66 | 26.22万美元 | 未持股 | 2026-10-09 |
| David J. Endicott | 男 | Director | 61 | 未披露 | 未持股 | 2026-10-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chad Spooner | 男 | Executive Vice President and Chief Financial Officer | 54 | 706.66万美元 | 1.92 | 2026-10-09 |
| Ali Dianaty | 男 | Executive Vice President, Chief Product and Technology Officer | 51 | 383.73万美元 | 0.72 | 2026-10-09 |
| Que Dallara | 女 | Chief Executive Officer and Director | 52 | 843.02万美元 | 3.43 | 2026-10-09 |
| Gillian Chandrasena | 女 | Senior Vice President, Chief Human Resources Officer | 52 | 260.58万美元 | 0.54 | 2026-10-09 |
董事简历
中英对照 | 中文 | 英文- Kevin E. Lofton
-
Kevin E. Lofton，自2019年2月Catholic Health Initiatives和 Dignity Health合并后担任CommonSpirit Health的首席执行官，直到2020年6月退休。从2003年到2019年，Lofton先生担任Catholic Health Initiatives的首席执行官，并从1998年开始担任Catholic Health Initiatives的各种执行管理职务。1993年至1998年，他担任UAB Hospital的执行董事兼首席执行官；1990年至1993年，担任Howard University Hospital的执行董事兼首席执行官；1986年至1990年，担任University Medical Center - Florida的执行副总裁兼首席运营官。此外，他还担任美国医院协会（美国最大的卫生系统贸易协会）的董事会主席。
Kevin E. Lofton has served as Chair of MiniMed's board since March 2026. Mr. Lofton has served as a Director of Medtronic since August 2020. In addition, Mr. Lofton is a Life Fellow of the American College of Healthcare Executives. Mr. Lofton served as Chief Executive Officer of CommonSpirit Health, a nonprofit health system, from 2019, following the merger between Catholic Health Initiatives ("CHI") and Dignity Health, until his retirement in 2020. Prior to the merger, Mr. Lofton served as Chief Executive Officer of CHI for 16 years. Before CHI, Mr. Lofton served in various leadership positions in healthcare organizations, including Chief Executive Officer of UAB Hospital, Chief Executive Officer of Howard University Hospital, and Executive Vice President and Chief Operating Officer of UF Health Jacksonville. Mr. Lofton served on the board of directors of Gilead Sciences, Inc., a biopharmaceutical company (Nasdaq: GILD) from July 2009 to May 2024, where he was the Lead Independent Director from 2020 to 2024 and from November 2013 to July 2022, Mr. Lofton served on the board of directors of Rite Aid Corporation, a retail pharmacy chain (NYSE: RAD). He also served as Chair of the board of the American Hospital Association, one of the largest healthcare trade associations in the country. Mr. Lofton holds a B.S. from Boston University and an MHA from Georgia State University. - Kevin E. Lofton，自2019年2月Catholic Health Initiatives和 Dignity Health合并后担任CommonSpirit Health的首席执行官，直到2020年6月退休。从2003年到2019年，Lofton先生担任Catholic Health Initiatives的首席执行官，并从1998年开始担任Catholic Health Initiatives的各种执行管理职务。1993年至1998年，他担任UAB Hospital的执行董事兼首席执行官；1990年至1993年，担任Howard University Hospital的执行董事兼首席执行官；1986年至1990年，担任University Medical Center - Florida的执行副总裁兼首席运营官。此外，他还担任美国医院协会（美国最大的卫生系统贸易协会）的董事会主席。
- Kevin E. Lofton has served as Chair of MiniMed's board since March 2026. Mr. Lofton has served as a Director of Medtronic since August 2020. In addition, Mr. Lofton is a Life Fellow of the American College of Healthcare Executives. Mr. Lofton served as Chief Executive Officer of CommonSpirit Health, a nonprofit health system, from 2019, following the merger between Catholic Health Initiatives ("CHI") and Dignity Health, until his retirement in 2020. Prior to the merger, Mr. Lofton served as Chief Executive Officer of CHI for 16 years. Before CHI, Mr. Lofton served in various leadership positions in healthcare organizations, including Chief Executive Officer of UAB Hospital, Chief Executive Officer of Howard University Hospital, and Executive Vice President and Chief Operating Officer of UF Health Jacksonville. Mr. Lofton served on the board of directors of Gilead Sciences, Inc., a biopharmaceutical company (Nasdaq: GILD) from July 2009 to May 2024, where he was the Lead Independent Director from 2020 to 2024 and from November 2013 to July 2022, Mr. Lofton served on the board of directors of Rite Aid Corporation, a retail pharmacy chain (NYSE: RAD). He also served as Chair of the board of the American Hospital Association, one of the largest healthcare trade associations in the country. Mr. Lofton holds a B.S. from Boston University and an MHA from Georgia State University.
- Glenn Eisenberg
-
格伦·艾森伯格自2026年3月起担任MiniMed董事会成员。艾森伯格先生于2014年6月至2024年12月期间，在全球生命科学公司徕博科控股公司（纽约证券交易所代码：LH）（“徕博科”）担任执行副总裁兼首席财务官，当时他宣布退休，并自2024年12月起担任徕博科的特别顾问。自2025年4月以来，艾森伯格先生一直担任私募股权公司罗纳集团的高级顾问。在加入徕博科之前，Eisenberg先生曾担任多个领导职务，包括工程轴承、运动控制产品和钢材（纽约证券交易所代码：TKR）制造商铁姆肯公司的财务和行政执行副总裁兼首席财务官，以及多元化工业制造商United Dominion Industries（纽约证券交易所代码：UDI）的总裁兼首席运营官。Eisenberg先生曾担任医疗保健技术公司Solventum Corporation（NYSE：SOLV）的董事会成员，自2024年4月起担任该公司的董事会成员，自2025年3月起担任门诊医学影像公司Lumexa Imaging Holdings，Inc.（纳斯达克：LMRI）的董事会成员，自2026年3月起担任商业餐饮服务设备制造商The Middleby Corporation（MIDD）的董事会成员。艾森伯格先生此前曾于2002年至2015年担任家万金百货（NYSE：FDO）的董事会成员、2019年5月至2021年5月担任美国政府IT服务提供商Perspecta Inc.（NYSE：PRSP）的董事会成员、2018年至2022年5月担任环境服务提供商美国生态，Inc.（纳斯达克：ECOL）的董事会成员，以及2005年3月至2009年7月担任阿尔法自然资源公司TERM5（NYSE：ANR）的董事会成员。艾森伯格先生拥有杜兰大学的学士学位和乔治亚州立大学的MBA学位。
Glenn Eisenberg has served on MiniMed's board since March 2026. Mr. Eisenberg served as Executive Vice President and Chief Financial Officer of Labcorp Holdings Inc. (NYSE: LH) ("Labcorp"), a global life sciences company, from June 2014 to December 2024, when he announced his retirement and has served as a Special Advisor to Labcorp since December 2024. Mr. Eisenberg has served as a Senior Advisor at Rhne Group, a private equity firm, since April 2025. Prior to joining Labcorp, Mr. Eisenberg served in various leadership positions, including Executive Vice President, Finance and Administration & Chief Financial Officer of The Timken Company, a manufacturer of engineered bearings, motion control products, and steel (NYSE: TKR), and President and Chief Operating Officer of the United Dominion Industries (NYSE: UDI), a diversified industrial manufacturer. Mr. Eisenberg has served on the boards of directors of Solventum Corporation, a healthcare technology company (NYSE: SOLV), since April 2024, Lumexa Imaging Holdings, Inc., an outpatient medical imaging company (Nasdaq: LMRI) since March 2025 and The Middleby Corporation, a commercial foodservice equipment manufacturer (Nasdaq: MIDD) since March 2026. Mr. Eisenberg previously served on the boards of directors of Family Dollar Stores, Inc. (NYSE: FDO) from 2002 to 2015, Perspecta Inc., a U.S. government IT services provider (NYSE: PRSP) from May 2019 to May 2021, US Ecology, Inc., an environmental services provder (Nasdaq: ECOL) from 2018 to May 2022, and Alpha Natural Resources, Inc. (NYSE: ANR) from March 2005 to July 2009. Mr. Eisenberg holds a B.A. from Tulane University and an MBA from Georgia State University. - 格伦·艾森伯格自2026年3月起担任MiniMed董事会成员。艾森伯格先生于2014年6月至2024年12月期间，在全球生命科学公司徕博科控股公司（纽约证券交易所代码：LH）（“徕博科”）担任执行副总裁兼首席财务官，当时他宣布退休，并自2024年12月起担任徕博科的特别顾问。自2025年4月以来，艾森伯格先生一直担任私募股权公司罗纳集团的高级顾问。在加入徕博科之前，Eisenberg先生曾担任多个领导职务，包括工程轴承、运动控制产品和钢材（纽约证券交易所代码：TKR）制造商铁姆肯公司的财务和行政执行副总裁兼首席财务官，以及多元化工业制造商United Dominion Industries（纽约证券交易所代码：UDI）的总裁兼首席运营官。Eisenberg先生曾担任医疗保健技术公司Solventum Corporation（NYSE：SOLV）的董事会成员，自2024年4月起担任该公司的董事会成员，自2025年3月起担任门诊医学影像公司Lumexa Imaging Holdings，Inc.（纳斯达克：LMRI）的董事会成员，自2026年3月起担任商业餐饮服务设备制造商The Middleby Corporation（MIDD）的董事会成员。艾森伯格先生此前曾于2002年至2015年担任家万金百货（NYSE：FDO）的董事会成员、2019年5月至2021年5月担任美国政府IT服务提供商Perspecta Inc.（NYSE：PRSP）的董事会成员、2018年至2022年5月担任环境服务提供商美国生态，Inc.（纳斯达克：ECOL）的董事会成员，以及2005年3月至2009年7月担任阿尔法自然资源公司TERM5（NYSE：ANR）的董事会成员。艾森伯格先生拥有杜兰大学的学士学位和乔治亚州立大学的MBA学位。
- Glenn Eisenberg has served on MiniMed's board since March 2026. Mr. Eisenberg served as Executive Vice President and Chief Financial Officer of Labcorp Holdings Inc. (NYSE: LH) ("Labcorp"), a global life sciences company, from June 2014 to December 2024, when he announced his retirement and has served as a Special Advisor to Labcorp since December 2024. Mr. Eisenberg has served as a Senior Advisor at Rhne Group, a private equity firm, since April 2025. Prior to joining Labcorp, Mr. Eisenberg served in various leadership positions, including Executive Vice President, Finance and Administration & Chief Financial Officer of The Timken Company, a manufacturer of engineered bearings, motion control products, and steel (NYSE: TKR), and President and Chief Operating Officer of the United Dominion Industries (NYSE: UDI), a diversified industrial manufacturer. Mr. Eisenberg has served on the boards of directors of Solventum Corporation, a healthcare technology company (NYSE: SOLV), since April 2024, Lumexa Imaging Holdings, Inc., an outpatient medical imaging company (Nasdaq: LMRI) since March 2025 and The Middleby Corporation, a commercial foodservice equipment manufacturer (Nasdaq: MIDD) since March 2026. Mr. Eisenberg previously served on the boards of directors of Family Dollar Stores, Inc. (NYSE: FDO) from 2002 to 2015, Perspecta Inc., a U.S. government IT services provider (NYSE: PRSP) from May 2019 to May 2021, US Ecology, Inc., an environmental services provder (Nasdaq: ECOL) from 2018 to May 2022, and Alpha Natural Resources, Inc. (NYSE: ANR) from March 2005 to July 2009. Mr. Eisenberg holds a B.A. from Tulane University and an MBA from Georgia State University.
- Matthew R. Walter
-
Matthew R. Walter自2026年3月起担任MiniMed董事会成员。自2023年7月起，Walter先生担任美敦力人力资源、IT以及Global Communications & Corp市场营销高级副总裁。Walter先生还担任美敦力执行委员会成员。2021年3月至2023年7月，Walter先生在美敦力担任全球运营和供应链人力资源副总裁。2018年12月至2022年2月，Walter先生在美敦力担任糖尿病运营部门人力资源副总裁。从2014年到2018年，Walter先生在美敦力担任过各种领导职务。在2014年加入美敦力之前，Walter先生曾在百思买公司（纽约证券交易所代码：BBY）担任人才管理高级总监。在此之前，他曾在美国银行（NYSE：BAC）担任多个领导职务。Walter先生在圣弗朗西斯大学获得心理学学士学位，在科罗拉多州立大学获得工业和组织心理学博士学位。
Matthew R. Walter has served on MiniMed's board since March 2026. Since July 2023, Mr. Walter has served as Senior Vice President, Human Resources, IT, and Global Communications & Corp Marketing of Medtronic. Mr. Walter also serves as a member of the Medtronic Executive Committee. From March 2021 to July 2023, Mr. Walter served as Vice President Human Resources of Global Operations and Supply Chain at Medtronic. From December 2018 to February 2022, Mr. Walter served as Vice President Human Resources of the Diabetes Operating Unit at Medtronic. From 2014 to 2018, Mr. Walter served in various leadership roles at Medtronic. Prior to joining Medtronic in 2014, Mr. Walter served as Senior Director of Talent Management at Best Buy Co., Inc. (NYSE: BBY). Prior to that, he held a number of leadership roles at Bank of America (NYSE: BAC). Mr. Walter earned a B.A. in Psychology from Saint Francis University and a Ph.D. in Industrial and Organizational Psychology from Colorado State University. - Matthew R. Walter自2026年3月起担任MiniMed董事会成员。自2023年7月起，Walter先生担任美敦力人力资源、IT以及Global Communications & Corp市场营销高级副总裁。Walter先生还担任美敦力执行委员会成员。2021年3月至2023年7月，Walter先生在美敦力担任全球运营和供应链人力资源副总裁。2018年12月至2022年2月，Walter先生在美敦力担任糖尿病运营部门人力资源副总裁。从2014年到2018年，Walter先生在美敦力担任过各种领导职务。在2014年加入美敦力之前，Walter先生曾在百思买公司（纽约证券交易所代码：BBY）担任人才管理高级总监。在此之前，他曾在美国银行（NYSE：BAC）担任多个领导职务。Walter先生在圣弗朗西斯大学获得心理学学士学位，在科罗拉多州立大学获得工业和组织心理学博士学位。
- Matthew R. Walter has served on MiniMed's board since March 2026. Since July 2023, Mr. Walter has served as Senior Vice President, Human Resources, IT, and Global Communications & Corp Marketing of Medtronic. Mr. Walter also serves as a member of the Medtronic Executive Committee. From March 2021 to July 2023, Mr. Walter served as Vice President Human Resources of Global Operations and Supply Chain at Medtronic. From December 2018 to February 2022, Mr. Walter served as Vice President Human Resources of the Diabetes Operating Unit at Medtronic. From 2014 to 2018, Mr. Walter served in various leadership roles at Medtronic. Prior to joining Medtronic in 2014, Mr. Walter served as Senior Director of Talent Management at Best Buy Co., Inc. (NYSE: BBY). Prior to that, he held a number of leadership roles at Bank of America (NYSE: BAC). Mr. Walter earned a B.A. in Psychology from Saint Francis University and a Ph.D. in Industrial and Organizational Psychology from Colorado State University.
- Robert A. Hopkins
-
Robert A. Hopkins自2026年3月起担任MiniMed董事会成员。自2021年11月起，霍普金斯先生担任美敦力高级副总裁兼全球战略主管以及美敦力执行委员会成员。2008年7月至2021年11月，霍普金斯先生在美国银行证券公司（f/k/a美银美林）（纽约证券交易所代码：BAC）担任董事总经理和高级股票研究分析师，该公司是一家银行控股公司和一家金融控股公司，业务涵盖医疗技术行业。他还曾在雷曼兄弟控股公司（Lehman Brothers Holdings Inc.）和唐纳森（Donaldson，Lufkin & Jenrette）担任过多个领导职务。霍普金斯先生拥有Hartford三一学院的学士学位和哥伦比亚商学院的MBA学位。
Robert A. Hopkins has served on MiniMed's board since March 2026. Since November 2021, Mr. Hopkins has served as Senior Vice President and Head of Global Strategy of Medtronic and Executive Committee member for Medtronic. From July 2008 to November 2021, Mr. Hopkins served as Managing Director and Senior Equity Research Analyst at BofA Securities, Inc. (f/k/a Bank of America Merrill Lynch) (NYSE: BAC), a bank holding company and a financial holding company, where he covered the medical technology industry. He also has held various leadership positions at Lehman Brothers Holdings Inc. and Donaldson, Lufkin & Jenrette. Mr. Hopkins holds a B.A. from Trinity College Hartford and an MBA from Columbia Business School. - Robert A. Hopkins自2026年3月起担任MiniMed董事会成员。自2021年11月起，霍普金斯先生担任美敦力高级副总裁兼全球战略主管以及美敦力执行委员会成员。2008年7月至2021年11月，霍普金斯先生在美国银行证券公司（f/k/a美银美林）（纽约证券交易所代码：BAC）担任董事总经理和高级股票研究分析师，该公司是一家银行控股公司和一家金融控股公司，业务涵盖医疗技术行业。他还曾在雷曼兄弟控股公司（Lehman Brothers Holdings Inc.）和唐纳森（Donaldson，Lufkin & Jenrette）担任过多个领导职务。霍普金斯先生拥有Hartford三一学院的学士学位和哥伦比亚商学院的MBA学位。
- Robert A. Hopkins has served on MiniMed's board since March 2026. Since November 2021, Mr. Hopkins has served as Senior Vice President and Head of Global Strategy of Medtronic and Executive Committee member for Medtronic. From July 2008 to November 2021, Mr. Hopkins served as Managing Director and Senior Equity Research Analyst at BofA Securities, Inc. (f/k/a Bank of America Merrill Lynch) (NYSE: BAC), a bank holding company and a financial holding company, where he covered the medical technology industry. He also has held various leadership positions at Lehman Brothers Holdings Inc. and Donaldson, Lufkin & Jenrette. Mr. Hopkins holds a B.A. from Trinity College Hartford and an MBA from Columbia Business School.
- Laura Mauri
-
Laura Mauri自2026年3月起担任MiniMed董事会成员。自2022年4月起，Mauri博士担任美敦力高级副总裁、首席科学和医疗官，并且是美敦力执行委员会成员。从2020年9月到2022年4月，Mauri博士在美敦力担任高级副总裁、首席临床和法规官。2018年9月至2020年9月，Mauri博士在美敦力担任全球临床研究和分析副总裁。Mauri博士还担任医疗器械创新联盟的董事会成员，该联盟是一家支持医疗器械开发和监管科学的非营利性公私合作伙伴关系，也是Mozarc Medical的薪酬委员会的成员，该公司是达维塔保健 Inc.和美敦力的合资企业。Mauri博士还担任过美国FDA、美国国立卫生研究院、CMS和美国国家医学研究院的顾问职务。在2018年加入美敦力之前，毛里博士在布莱根妇女医院担任了15年的介入心脏病专家，并担任哈佛医学院的医学教授。Mauri博士拥有哈佛学院的A.B.学位、哈佛公共卫生学院的理学硕士学位和哈佛医学院的医学博士学位。
Laura Mauri has served on MiniMed's board since March 2026. Since April 2022, Dr. Mauri has served as Senior Vice President, Chief Scientific and Medical Officer at Medtronic and is a member of the Medtronic Executive Committee. From September 2020 until April 2022, Dr. Mauri served as Senior Vice President, Chief Clinical and Regulatory Officer at Medtronic. From September 2018 until September 2020, Dr. Mauri served as Vice President of Global Clinical Research and Analytics at Medtronic. Dr. Mauri also serves on the board of directors of the Medical Device Innovation Consortium, a nonprofit public private partnership supporting medical device development and regulatory science and the Compensation Committee of Mozarc Medical, a joint venture of DaVita Inc. and Medtronic. Dr. Mauri has also held advisory roles with the U.S. FDA, the NIH, the CMS, and the National Academy of Medicine. Prior to joining Medtronic in 2018, Dr. Mauri spent 15 years as an interventional cardiologist at Brigham and Women's Hospital and served as Professor of Medicine at Harvard Medical School. Dr. Mauri holds an A.B. from Harvard College, an M.Sc. from Harvard School of Public Health, and an M.D. from Harvard Medical School. - Laura Mauri自2026年3月起担任MiniMed董事会成员。自2022年4月起，Mauri博士担任美敦力高级副总裁、首席科学和医疗官，并且是美敦力执行委员会成员。从2020年9月到2022年4月，Mauri博士在美敦力担任高级副总裁、首席临床和法规官。2018年9月至2020年9月，Mauri博士在美敦力担任全球临床研究和分析副总裁。Mauri博士还担任医疗器械创新联盟的董事会成员，该联盟是一家支持医疗器械开发和监管科学的非营利性公私合作伙伴关系，也是Mozarc Medical的薪酬委员会的成员，该公司是达维塔保健 Inc.和美敦力的合资企业。Mauri博士还担任过美国FDA、美国国立卫生研究院、CMS和美国国家医学研究院的顾问职务。在2018年加入美敦力之前，毛里博士在布莱根妇女医院担任了15年的介入心脏病专家，并担任哈佛医学院的医学教授。Mauri博士拥有哈佛学院的A.B.学位、哈佛公共卫生学院的理学硕士学位和哈佛医学院的医学博士学位。
- Laura Mauri has served on MiniMed's board since March 2026. Since April 2022, Dr. Mauri has served as Senior Vice President, Chief Scientific and Medical Officer at Medtronic and is a member of the Medtronic Executive Committee. From September 2020 until April 2022, Dr. Mauri served as Senior Vice President, Chief Clinical and Regulatory Officer at Medtronic. From September 2018 until September 2020, Dr. Mauri served as Vice President of Global Clinical Research and Analytics at Medtronic. Dr. Mauri also serves on the board of directors of the Medical Device Innovation Consortium, a nonprofit public private partnership supporting medical device development and regulatory science and the Compensation Committee of Mozarc Medical, a joint venture of DaVita Inc. and Medtronic. Dr. Mauri has also held advisory roles with the U.S. FDA, the NIH, the CMS, and the National Academy of Medicine. Prior to joining Medtronic in 2018, Dr. Mauri spent 15 years as an interventional cardiologist at Brigham and Women's Hospital and served as Professor of Medicine at Harvard Medical School. Dr. Mauri holds an A.B. from Harvard College, an M.Sc. from Harvard School of Public Health, and an M.D. from Harvard Medical School.
- Que Dallara
-
自2026年3月起，Que Dallara担任MiniMed的首席执行官和董事。2022年5月至2026年3月，Dallara女士担任美敦力糖尿病运营部门执行副总裁兼运营部门总裁。从2018年10月到2022年4月，Dallara女士担任霍尼韦尔 Connected Enterprise的总裁兼首席执行官，该公司是一家多元化的工业集团企业霍尼韦尔国际公司的软件业务。2017年1月至2019年10月，Dallara女士担任霍尼韦尔高级副总裁兼首席商务官。在2017年加入霍尼韦尔之前，Dallara女士曾在泰科电子、微软、ITV | world、Telstra Corporation、麦肯锡公司任职。Dallara女士自2023年11月起担任Lattice Semiconductor Corporation（纳斯达克：LSCC）的董事会成员。Dallara女士拥有新南威尔士大学应用数学（荣誉1级）和BCoM的理学学士学位，以及法国INSEAD的MBA学位。
Que Dallara has served as Chief Executive Officer and a Director of MiniMed since March 2026. From May 2022 to March 2026, Ms. Dallara served as Executive Vice President and Operating Unit President of the Diabetes Operating Unit of Medtronic. From October 2018 to April 2022, Ms. Dallara served as President and Chief Executive Officer of Honeywell Connected Enterprise, the software business of Honeywell International, Inc., a diversified industrial conglomerate. From January 2017 to October 2019, Ms. Dallara served as Senior Vice President and Chief Commercial Officer of Honeywell. Before joining Honeywell in 2017, Ms. Dallara worked at TE Connectivity, Microsoft, itv|world, Telstra Corporation, and McKinsey & Company. Ms. Dallara has served on the board of directors of Lattice Semiconductor Corporation (Nasdaq: LSCC) since November 2023. Ms. Dallara holds a BSc. in Applied Mathematics (Honours Class 1) and BCom from the University of New South Wales and an MBA from INSEAD in France. - 自2026年3月起，Que Dallara担任MiniMed的首席执行官和董事。2022年5月至2026年3月，Dallara女士担任美敦力糖尿病运营部门执行副总裁兼运营部门总裁。从2018年10月到2022年4月，Dallara女士担任霍尼韦尔 Connected Enterprise的总裁兼首席执行官，该公司是一家多元化的工业集团企业霍尼韦尔国际公司的软件业务。2017年1月至2019年10月，Dallara女士担任霍尼韦尔高级副总裁兼首席商务官。在2017年加入霍尼韦尔之前，Dallara女士曾在泰科电子、微软、ITV | world、Telstra Corporation、麦肯锡公司任职。Dallara女士自2023年11月起担任Lattice Semiconductor Corporation（纳斯达克：LSCC）的董事会成员。Dallara女士拥有新南威尔士大学应用数学（荣誉1级）和BCoM的理学学士学位，以及法国INSEAD的MBA学位。
- Que Dallara has served as Chief Executive Officer and a Director of MiniMed since March 2026. From May 2022 to March 2026, Ms. Dallara served as Executive Vice President and Operating Unit President of the Diabetes Operating Unit of Medtronic. From October 2018 to April 2022, Ms. Dallara served as President and Chief Executive Officer of Honeywell Connected Enterprise, the software business of Honeywell International, Inc., a diversified industrial conglomerate. From January 2017 to October 2019, Ms. Dallara served as Senior Vice President and Chief Commercial Officer of Honeywell. Before joining Honeywell in 2017, Ms. Dallara worked at TE Connectivity, Microsoft, itv|world, Telstra Corporation, and McKinsey & Company. Ms. Dallara has served on the board of directors of Lattice Semiconductor Corporation (Nasdaq: LSCC) since November 2023. Ms. Dallara holds a BSc. in Applied Mathematics (Honours Class 1) and BCom from the University of New South Wales and an MBA from INSEAD in France.
- Linnea Burman
-
Linnea Burman自2026年6月起担任MiniMed董事会成员。自2024年4月起，Burman女士担任美敦力 PLC高级副总裁兼神经血管总裁。2020年5月至2024年5月，Burman女士在美敦力担任Enabling Technologies：Cranial & Spinal Technologies副总裁兼总经理。在担任这些职务之前，Burman女士在美敦力担任过多个领导职务，任职时间超过19年，包括副总裁兼总经理，负责盆腔健康和胃疗法、神经科学战略规划与传播副总裁，以及美国疼痛刺激和靶向给药市场营销总监，以及更早的营销和市场开发职务。布尔曼女士拥有传播学学士学位，重点是弗吉尼亚理工大学的公共关系专业。
Linnea Burman has served on MiniMed's board since June 2026. Since April 2024, Ms. Burman has served as Senior Vice President & President, Neurovascular at Medtronic plc. From May 2020 to May 2024, Ms. Burman served as Vice President & General Manager, Enabling Technologies: Cranial & Spinal Technologies at Medtronic. Prior to these roles, Ms. Burman held various leadership positions at Medtronic over a tenure spanning more than 19 years, including Vice President & General Manager, Pelvic Health & Gastric Therapies, Neurosciences Vice President of Strategic Planning & Communications, and Director of Marketing, US Pain Stimulation & Targeted Drug Delivery, as well as earlier marketing and market development roles. Ms. Burman holds a B.A. in Communication Studies, with an emphasis in Public Relations from Virginia Tech. - Linnea Burman自2026年6月起担任MiniMed董事会成员。自2024年4月起，Burman女士担任美敦力 PLC高级副总裁兼神经血管总裁。2020年5月至2024年5月，Burman女士在美敦力担任Enabling Technologies：Cranial & Spinal Technologies副总裁兼总经理。在担任这些职务之前，Burman女士在美敦力担任过多个领导职务，任职时间超过19年，包括副总裁兼总经理，负责盆腔健康和胃疗法、神经科学战略规划与传播副总裁，以及美国疼痛刺激和靶向给药市场营销总监，以及更早的营销和市场开发职务。布尔曼女士拥有传播学学士学位，重点是弗吉尼亚理工大学的公共关系专业。
- Linnea Burman has served on MiniMed's board since June 2026. Since April 2024, Ms. Burman has served as Senior Vice President & President, Neurovascular at Medtronic plc. From May 2020 to May 2024, Ms. Burman served as Vice President & General Manager, Enabling Technologies: Cranial & Spinal Technologies at Medtronic. Prior to these roles, Ms. Burman held various leadership positions at Medtronic over a tenure spanning more than 19 years, including Vice President & General Manager, Pelvic Health & Gastric Therapies, Neurosciences Vice President of Strategic Planning & Communications, and Director of Marketing, US Pain Stimulation & Targeted Drug Delivery, as well as earlier marketing and market development roles. Ms. Burman holds a B.A. in Communication Studies, with an emphasis in Public Relations from Virginia Tech.
- Scott Cundy
-
Scott Cundy自2026年7月起担任MiniMed董事会成员。自2025年11月起，Cundy先生担任美敦力高级副总裁兼首席质量、发展与创新官。自2023年1月9日起，Cundy先生担任美敦力执行委员会成员。自2025年5月起，Cundy先生担任美敦力高级副总裁兼首席质量与发展官。2023年1月至2025年5月，Cundy先生在美敦力担任高级副总裁兼首席质量官。在2023年加入美敦力之前，Cundy先生于2020年10月至2023年1月在丹纳赫公司（NYSE：DHR）担任质量、监管、临床事务诊断和生命科学平台副总裁，于2018年11月至2020年10月在丹纳赫公司担任RA/QA诊断和生命科学平台副总裁，于2014年6月至2018年11月在丹纳赫公司担任RA/QA生命科学平台副总裁，于2010年6月至2014年6月在丹纳赫公司担任RA/QA 贝克曼库尔特 immunoAssay副总裁。Cundy先生拥有佐治亚理工学院工业工程学士学位和明尼苏达大学卡尔森管理学院MBA学位。
Scott Cundy has served on MiniMed's board since July 2026. Since November 2025, Mr. Cundy has served as Senior Vice President and Chief Quality, Development, & Innovation Officer at Medtronic. Since January 9, 2023, Mr. Cundy has served as a member of the Medtronic Executive Committee. Since May 2025, Mr. Cundy has served as Senior Vice President and Chief Quality and Development Officer at Medtronic. From January 2023 until May 2025, Mr. Cundy served as Senior Vice President and Chief Quality officer at Medtronic. Prior to joining Medtronic in 2023, Mr. Cundy served as VP Quality, Regulatory, & Clinical Affairs Diagnostics and Life Sciences Platforms at Danaher Corporation (NYSE: DHR) from October 2020 to January 2023, as VP RA/QA Diagnostics & Life Sciences Platforms at Danaher Corporation from November 2018 to October 2020, as VP RA/QA Life Sciences Platform at Danaher Corporation from June 2014 until November 2018, and VP RA/QA Beckman Coulter ImmunoAssay at Danaher Corporation from June 2010 to June 2014. Mr. Cundy holds a B.S. in Industrial Engineering from Georgia Tech and an MBA from the University of Minnesota's Carlson School of Management. - Scott Cundy自2026年7月起担任MiniMed董事会成员。自2025年11月起，Cundy先生担任美敦力高级副总裁兼首席质量、发展与创新官。自2023年1月9日起，Cundy先生担任美敦力执行委员会成员。自2025年5月起，Cundy先生担任美敦力高级副总裁兼首席质量与发展官。2023年1月至2025年5月，Cundy先生在美敦力担任高级副总裁兼首席质量官。在2023年加入美敦力之前，Cundy先生于2020年10月至2023年1月在丹纳赫公司（NYSE：DHR）担任质量、监管、临床事务诊断和生命科学平台副总裁，于2018年11月至2020年10月在丹纳赫公司担任RA/QA诊断和生命科学平台副总裁，于2014年6月至2018年11月在丹纳赫公司担任RA/QA生命科学平台副总裁，于2010年6月至2014年6月在丹纳赫公司担任RA/QA 贝克曼库尔特 immunoAssay副总裁。Cundy先生拥有佐治亚理工学院工业工程学士学位和明尼苏达大学卡尔森管理学院MBA学位。
- Scott Cundy has served on MiniMed's board since July 2026. Since November 2025, Mr. Cundy has served as Senior Vice President and Chief Quality, Development, & Innovation Officer at Medtronic. Since January 9, 2023, Mr. Cundy has served as a member of the Medtronic Executive Committee. Since May 2025, Mr. Cundy has served as Senior Vice President and Chief Quality and Development Officer at Medtronic. From January 2023 until May 2025, Mr. Cundy served as Senior Vice President and Chief Quality officer at Medtronic. Prior to joining Medtronic in 2023, Mr. Cundy served as VP Quality, Regulatory, & Clinical Affairs Diagnostics and Life Sciences Platforms at Danaher Corporation (NYSE: DHR) from October 2020 to January 2023, as VP RA/QA Diagnostics & Life Sciences Platforms at Danaher Corporation from November 2018 to October 2020, as VP RA/QA Life Sciences Platform at Danaher Corporation from June 2014 until November 2018, and VP RA/QA Beckman Coulter ImmunoAssay at Danaher Corporation from June 2010 to June 2014. Mr. Cundy holds a B.S. in Industrial Engineering from Georgia Tech and an MBA from the University of Minnesota's Carlson School of Management.
- Timothy A. Wicks
-
Timothy A. Wicks，他担任YRC Worldwide的总裁兼首席运营官（2009年10月以来）、YRC Worldwide的执行副总裁兼首席财务官（2008年10月到2009年10月）、战略增长计划高级副总裁（2006年到2008年）、产品发展和管理高级副总裁（2004年到2006年）、白金代理服务副总裁（2003年到2004年）、United Healthcare （医疗保险）的消费者的解决方案副总裁（2002年到2003年）。
Timothy A. Wicks has served on MiniMed's board since March 2026. Since April 2024, Mr. Wicks has served on the board of directors of BrightSpring Health Services, Inc., a provider of home and community based health services (Nasdaq: BTSG). Since May 2026, Mr. Wicks has served on the board of directors of GMR Solutions, Inc., an emergency medical services provider (NYSE: GMRS). From June 2022 to April 2023, Mr. Wicks served on the board of directors of Pear Therapeutics, Inc., a digital therapeutics company developing prescription software based treatments (Nasdaq: Pear). Mr. Wicks has served on the board of directors of MOBE, LLC, a health guidance company, since April 2023. Mr. Wicks has acted as an Advisor to the healthcare practice of KKR & Co. Inc, a private equity and investment firm, since June 2024. From 2002 until his retirement in 2021, Mr. Wicks served in various executive leadership roles at UnitedHealthcare, Optum, and OptumRX, divisions of UnitedHealth Group, Incorporated, a healthcare and health insurance company (NYSE: UNH), including executive oversight for Optum Financial Services, Executive Vice President of Supply Chain, Chief Executive Officer and President of OptumRx, and Chief Financial Officer of Optum. Mr. Wicks also served as Chief Financial Officer and then President and Chief Operating Officer of Yellow Corporation and President of Great Northern Capital. Mr. Wicks has also served on the boards of directors of Precision Castparts Corp., and Aerojet Rocketdyne. Mr. Wicks holds a B.A. from the University of Chicago and an MBA from Harvard University's Graduate School of Business. - Timothy A. Wicks，他担任YRC Worldwide的总裁兼首席运营官（2009年10月以来）、YRC Worldwide的执行副总裁兼首席财务官（2008年10月到2009年10月）、战略增长计划高级副总裁（2006年到2008年）、产品发展和管理高级副总裁（2004年到2006年）、白金代理服务副总裁（2003年到2004年）、United Healthcare （医疗保险）的消费者的解决方案副总裁（2002年到2003年）。
- Timothy A. Wicks has served on MiniMed's board since March 2026. Since April 2024, Mr. Wicks has served on the board of directors of BrightSpring Health Services, Inc., a provider of home and community based health services (Nasdaq: BTSG). Since May 2026, Mr. Wicks has served on the board of directors of GMR Solutions, Inc., an emergency medical services provider (NYSE: GMRS). From June 2022 to April 2023, Mr. Wicks served on the board of directors of Pear Therapeutics, Inc., a digital therapeutics company developing prescription software based treatments (Nasdaq: Pear). Mr. Wicks has served on the board of directors of MOBE, LLC, a health guidance company, since April 2023. Mr. Wicks has acted as an Advisor to the healthcare practice of KKR & Co. Inc, a private equity and investment firm, since June 2024. From 2002 until his retirement in 2021, Mr. Wicks served in various executive leadership roles at UnitedHealthcare, Optum, and OptumRX, divisions of UnitedHealth Group, Incorporated, a healthcare and health insurance company (NYSE: UNH), including executive oversight for Optum Financial Services, Executive Vice President of Supply Chain, Chief Executive Officer and President of OptumRx, and Chief Financial Officer of Optum. Mr. Wicks also served as Chief Financial Officer and then President and Chief Operating Officer of Yellow Corporation and President of Great Northern Capital. Mr. Wicks has also served on the boards of directors of Precision Castparts Corp., and Aerojet Rocketdyne. Mr. Wicks holds a B.A. from the University of Chicago and an MBA from Harvard University's Graduate School of Business.
- D. Keith Grossman
-
D. Keith Grossman，在医疗器械和用品领域拥有超过35年的经验，包括担任医疗保健上市公司的首席执行官。他自2019年3月起担任Nevro的董事长、首席执行官兼总裁。他还自2014年起担任Outset Medical董事会主席。他于1996年至2006年以及2014年至2015年担任Thoratec Corporation的总裁兼首席执行官，并于1996年至2015年担任董事会成员。Grossman先生曾于2011年至2013年担任Conceptus公司的首席执行官和董事会成员。2007年至2011年担任TPG资本有限公司董事总经理兼高级顾问。Grossman先生还曾于2018年至2021年担任ViewRay，Inc.董事会成员，Zeltiq，Inc.于2013年至2017年担任首席董事，于2004年至2010年担任Intuitive Surgical，Inc.董事，Kyphon Inc.于2007年担任董事，并在多个私人董事会任职。Grossman先生拥有俄亥俄州立大学动物科学学士学位和美国佩珀代因大学佩珀代因格拉齐亚迪奥商学院金融工商管理硕士学位。
D. Keith Grossman has served on MiniMed's board since March 2026. Since February 2022, Mr. Grossman has served as Lead Independent Director at Outset Medical, Inc., a medical device company focused on home hemodialysis systems (Nasdaq: OM). From April 2014 to February 2022, Mr. Grossman served as Chairman of the board of directors for Outset Medical, Inc. Mr. Grossman served as Chairman of the board of directors of Nevro Corp., a medical device company specializing in spinal cord stimulation for chronic pain treatment (NYSE: NVRO), from March 2019 through April 2025 when the company was acquired by Globus Medical, Inc., previously serving as Nevro's Chief Executive Officer from March 2019 to April 2023 and as Executive Chairman from April 2023 to October 2023. Mr. Grossman has also served as Vice Chairman of Alcon Inc. (NYSE: ALC), an eye care products company, since April 2019. Previously, he was Chief Executive Officer and President of Thoratec (Nasdaq: THOR), a medical device company, from September 2014 to December 2015 and from January 1996 to January 2006; Chief Executive Officer and President of Conceptus (Nasdaq: CPTS), a manufacturer and developer of medical devices, from December 2011 to June 2013; and Managing Director of TPG (NASDAQ: TPG), a private equity firm, from September 2007 to December 2011. Mr. Grossman has also served on the board of directors of ViewRay, Inc., Intuitive Surgical, Kyphon, Inc., and Zeltiq Aesthetics, Inc. Mr. Grossman holds a B.S. from The Ohio State University and an M.B.A. from the Pepperdine Graziadio Business School. - D. Keith Grossman，在医疗器械和用品领域拥有超过35年的经验，包括担任医疗保健上市公司的首席执行官。他自2019年3月起担任Nevro的董事长、首席执行官兼总裁。他还自2014年起担任Outset Medical董事会主席。他于1996年至2006年以及2014年至2015年担任Thoratec Corporation的总裁兼首席执行官，并于1996年至2015年担任董事会成员。Grossman先生曾于2011年至2013年担任Conceptus公司的首席执行官和董事会成员。2007年至2011年担任TPG资本有限公司董事总经理兼高级顾问。Grossman先生还曾于2018年至2021年担任ViewRay，Inc.董事会成员，Zeltiq，Inc.于2013年至2017年担任首席董事，于2004年至2010年担任Intuitive Surgical，Inc.董事，Kyphon Inc.于2007年担任董事，并在多个私人董事会任职。Grossman先生拥有俄亥俄州立大学动物科学学士学位和美国佩珀代因大学佩珀代因格拉齐亚迪奥商学院金融工商管理硕士学位。
- D. Keith Grossman has served on MiniMed's board since March 2026. Since February 2022, Mr. Grossman has served as Lead Independent Director at Outset Medical, Inc., a medical device company focused on home hemodialysis systems (Nasdaq: OM). From April 2014 to February 2022, Mr. Grossman served as Chairman of the board of directors for Outset Medical, Inc. Mr. Grossman served as Chairman of the board of directors of Nevro Corp., a medical device company specializing in spinal cord stimulation for chronic pain treatment (NYSE: NVRO), from March 2019 through April 2025 when the company was acquired by Globus Medical, Inc., previously serving as Nevro's Chief Executive Officer from March 2019 to April 2023 and as Executive Chairman from April 2023 to October 2023. Mr. Grossman has also served as Vice Chairman of Alcon Inc. (NYSE: ALC), an eye care products company, since April 2019. Previously, he was Chief Executive Officer and President of Thoratec (Nasdaq: THOR), a medical device company, from September 2014 to December 2015 and from January 1996 to January 2006; Chief Executive Officer and President of Conceptus (Nasdaq: CPTS), a manufacturer and developer of medical devices, from December 2011 to June 2013; and Managing Director of TPG (NASDAQ: TPG), a private equity firm, from September 2007 to December 2011. Mr. Grossman has also served on the board of directors of ViewRay, Inc., Intuitive Surgical, Kyphon, Inc., and Zeltiq Aesthetics, Inc. Mr. Grossman holds a B.S. from The Ohio State University and an M.B.A. from the Pepperdine Graziadio Business School.
- David J. Endicott
-
David J. Endicott，自2012年11月以来，是本公司的一位董事会成员。他目前是一家全球医药公司- Hospira Medical Devices的总裁。在这个职位之前，他曾于2011年4月-2013年7月期间，担任Allergan Medical的公司副总裁和总裁。在那之前，他曾于2004年10月-2010年8月期间，担任欧洲（Europe）、非洲（Africa）、中东（Middle East）的公司副总裁和总裁，以及管理Allergan的国际业务，包括协助Allergan进入新市场（如土耳其（Turkey）和波兰（Poland））。2004年1月-2004年10月期间，曾在U.S. Specialty Pharmaceuticals担任高级副总裁；2000年2月-2003年12月期间，曾担任加拿大（Canada）副总裁和总经理；以及自1998年以来，是U.S. Managed Markets的副总裁。在那之前，Endicott先生曾在1986年加入Allergan以来，在Allergan担任各种职位。他拥有Whitman大学的化学专业本科学位，以及Southern California大学的工商管理硕士学位。他还是哈佛商学院（Harvard Business School）的高级管理课程毕业生。
David J. Endicott, a lifelong healthcare executive with leadership experience at global pharmaceutical and medical device companies, David J. Endicott is the Chief Executive Officer of Alcon. He joined the Alcon Division, when still operating under the Novartis group, in July 2016 as President, Commercial and Innovation, and Chief Operating Officer. Prior to joining the Alcon Division in 2016 Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. Before joining Hospira, Mr. Endicott served as an officer and executive committee member of Allergan, Inc. where he spent more than 25 years of his career in leadership roles across Europe, Asia and Latin America, as well as the U.S. Mr. Endicott served on the board of directors of Zeltiq, Inc. and Orexigen Therapeutics, Inc. He currently serves on the board of AdvaMed. He holds an undergraduate degree in Chemistry from Whitman College and a Master’s degree in Business Administration from the University of Southern California, both in the United States. - David J. Endicott，自2012年11月以来，是本公司的一位董事会成员。他目前是一家全球医药公司- Hospira Medical Devices的总裁。在这个职位之前，他曾于2011年4月-2013年7月期间，担任Allergan Medical的公司副总裁和总裁。在那之前，他曾于2004年10月-2010年8月期间，担任欧洲（Europe）、非洲（Africa）、中东（Middle East）的公司副总裁和总裁，以及管理Allergan的国际业务，包括协助Allergan进入新市场（如土耳其（Turkey）和波兰（Poland））。2004年1月-2004年10月期间，曾在U.S. Specialty Pharmaceuticals担任高级副总裁；2000年2月-2003年12月期间，曾担任加拿大（Canada）副总裁和总经理；以及自1998年以来，是U.S. Managed Markets的副总裁。在那之前，Endicott先生曾在1986年加入Allergan以来，在Allergan担任各种职位。他拥有Whitman大学的化学专业本科学位，以及Southern California大学的工商管理硕士学位。他还是哈佛商学院（Harvard Business School）的高级管理课程毕业生。
- David J. Endicott, a lifelong healthcare executive with leadership experience at global pharmaceutical and medical device companies, David J. Endicott is the Chief Executive Officer of Alcon. He joined the Alcon Division, when still operating under the Novartis group, in July 2016 as President, Commercial and Innovation, and Chief Operating Officer. Prior to joining the Alcon Division in 2016 Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. Before joining Hospira, Mr. Endicott served as an officer and executive committee member of Allergan, Inc. where he spent more than 25 years of his career in leadership roles across Europe, Asia and Latin America, as well as the U.S. Mr. Endicott served on the board of directors of Zeltiq, Inc. and Orexigen Therapeutics, Inc. He currently serves on the board of AdvaMed. He holds an undergraduate degree in Chemistry from Whitman College and a Master’s degree in Business Administration from the University of Southern California, both in the United States.
高管简历
中英对照 | 中文 | 英文- Chad Spooner
Chad Spooner自2026年3月起担任MiniMed执行副总裁兼首席财务官。从2025年7月到2026年3月，Spooner先生在美敦力担任糖尿病运营部门的首席财务官。2020年7月至2025年7月，Spooner先生在消费品公司Soci é t é Bic S.A.（BB：PA）（“BIC”）担任首席财务官。在2020年加入BIC之前，Spooner先生曾担任Wolser Holdings，Inc.（d/b/a Slingshot Health）的首席财务官和Raffaela Apparel Group的首席财务官，并曾在通用电气担任多个领导职务，并在GE Energy担任高级财务职务。Spooner先生还在Tenex资本管理公司共同创立并担任高级运营财务职务。斯普纳先生拥有麻省理工学院的学士学位。
Chad Spooner has served as Executive Vice President & Chief Financial Officer of MiniMed since March 2026. From July 2025 to March 2026, Mr. Spooner served as the Chief Financial Officer of the Diabetes Operating Unit at Medtronic. From July 2020 to July 2025, Mr. Spooner served as Chief Financial Officer of Société Bic S.A., a consumer goods company (BB: PA) ("BIC"). Prior to joining BIC in 2020, Mr. Spooner served as Chief Financial Officer of Wolser Holdings, Inc. (d/b/a Slingshot Health) and Chief Financial Officer of Raffaela Apparel Group, and held various leadership positions at General Electric as well as a senior finance role at GE Energy. Mr. Spooner also co founded and held senior operational finance roles at Tenex Capital Management. Mr. Spooner holds a B.S. from the Massachusetts Institute of Technology.- Chad Spooner自2026年3月起担任MiniMed执行副总裁兼首席财务官。从2025年7月到2026年3月，Spooner先生在美敦力担任糖尿病运营部门的首席财务官。2020年7月至2025年7月，Spooner先生在消费品公司Soci é t é Bic S.A.（BB：PA）（“BIC”）担任首席财务官。在2020年加入BIC之前，Spooner先生曾担任Wolser Holdings，Inc.（d/b/a Slingshot Health）的首席财务官和Raffaela Apparel Group的首席财务官，并曾在通用电气担任多个领导职务，并在GE Energy担任高级财务职务。Spooner先生还在Tenex资本管理公司共同创立并担任高级运营财务职务。斯普纳先生拥有麻省理工学院的学士学位。
- Chad Spooner has served as Executive Vice President & Chief Financial Officer of MiniMed since March 2026. From July 2025 to March 2026, Mr. Spooner served as the Chief Financial Officer of the Diabetes Operating Unit at Medtronic. From July 2020 to July 2025, Mr. Spooner served as Chief Financial Officer of Société Bic S.A., a consumer goods company (BB: PA) ("BIC"). Prior to joining BIC in 2020, Mr. Spooner served as Chief Financial Officer of Wolser Holdings, Inc. (d/b/a Slingshot Health) and Chief Financial Officer of Raffaela Apparel Group, and held various leadership positions at General Electric as well as a senior finance role at GE Energy. Mr. Spooner also co founded and held senior operational finance roles at Tenex Capital Management. Mr. Spooner holds a B.S. from the Massachusetts Institute of Technology.
- Ali Dianaty
Ali Dianaty自2026年3月起担任MiniMed执行副总裁、首席产品与技术官。从2021年11月到2026年3月，Dianaty先生在美敦力担任糖尿病运营部门产品创新和运营高级副总裁。2020年3月至2021年11月，Dianaty先生在美敦力担任糖尿病运营部门研发、临床和监管副总裁。2016年5月至2021年11月，Dianaty先生在美敦力担任糖尿病运营部门研发副总裁。在2016年加入美敦力之前，Dianaty先生曾在圣犹达医疗和航空航天和国防制造商The Boeing Company工作。Dianaty先生拥有加州州立大学北岭分校的学士和理学硕士学位，以及加州大学洛杉矶分校安德森管理学院的MBA学位。
Ali Dianaty has served as Executive Vice President, Chief Product & Technology Officer of MiniMed since March 2026. From November 2021 to March 2026, Mr. Dianaty served as Senior Vice President of Product Innovation and Operations of the Diabetes Operating Unit at Medtronic. From March 2020 to November 2021, Mr. Dianaty served as Vice President, Research & Development, Clinical, and Regulatory, of the Diabetes Operating Unit at Medtronic. From May 2016 to November 2021, Mr. Dianaty served as Vice President Research & Development of the Diabetes Operating Unit at Medtronic. Prior to joining Medtronic in 2016, Mr. Dianaty worked at St. Jude Medical and The Boeing Company, an aerospace and defense manufacturer. Mr. Dianaty holds a B.S. and an M.Sc. from California State University, Northridge, and an MBA from the UCLA Anderson School of Management.- Ali Dianaty自2026年3月起担任MiniMed执行副总裁、首席产品与技术官。从2021年11月到2026年3月，Dianaty先生在美敦力担任糖尿病运营部门产品创新和运营高级副总裁。2020年3月至2021年11月，Dianaty先生在美敦力担任糖尿病运营部门研发、临床和监管副总裁。2016年5月至2021年11月，Dianaty先生在美敦力担任糖尿病运营部门研发副总裁。在2016年加入美敦力之前，Dianaty先生曾在圣犹达医疗和航空航天和国防制造商The Boeing Company工作。Dianaty先生拥有加州州立大学北岭分校的学士和理学硕士学位，以及加州大学洛杉矶分校安德森管理学院的MBA学位。
- Ali Dianaty has served as Executive Vice President, Chief Product & Technology Officer of MiniMed since March 2026. From November 2021 to March 2026, Mr. Dianaty served as Senior Vice President of Product Innovation and Operations of the Diabetes Operating Unit at Medtronic. From March 2020 to November 2021, Mr. Dianaty served as Vice President, Research & Development, Clinical, and Regulatory, of the Diabetes Operating Unit at Medtronic. From May 2016 to November 2021, Mr. Dianaty served as Vice President Research & Development of the Diabetes Operating Unit at Medtronic. Prior to joining Medtronic in 2016, Mr. Dianaty worked at St. Jude Medical and The Boeing Company, an aerospace and defense manufacturer. Mr. Dianaty holds a B.S. and an M.Sc. from California State University, Northridge, and an MBA from the UCLA Anderson School of Management.
- Que Dallara
自2026年3月起，Que Dallara担任MiniMed的首席执行官和董事。2022年5月至2026年3月，Dallara女士担任美敦力糖尿病运营部门执行副总裁兼运营部门总裁。从2018年10月到2022年4月，Dallara女士担任霍尼韦尔 Connected Enterprise的总裁兼首席执行官，该公司是一家多元化的工业集团企业霍尼韦尔国际公司的软件业务。2017年1月至2019年10月，Dallara女士担任霍尼韦尔高级副总裁兼首席商务官。在2017年加入霍尼韦尔之前，Dallara女士曾在泰科电子、微软、ITV | world、Telstra Corporation、麦肯锡公司任职。Dallara女士自2023年11月起担任Lattice Semiconductor Corporation（纳斯达克：LSCC）的董事会成员。Dallara女士拥有新南威尔士大学应用数学（荣誉1级）和BCoM的理学学士学位，以及法国INSEAD的MBA学位。
Que Dallara has served as Chief Executive Officer and a Director of MiniMed since March 2026. From May 2022 to March 2026, Ms. Dallara served as Executive Vice President and Operating Unit President of the Diabetes Operating Unit of Medtronic. From October 2018 to April 2022, Ms. Dallara served as President and Chief Executive Officer of Honeywell Connected Enterprise, the software business of Honeywell International, Inc., a diversified industrial conglomerate. From January 2017 to October 2019, Ms. Dallara served as Senior Vice President and Chief Commercial Officer of Honeywell. Before joining Honeywell in 2017, Ms. Dallara worked at TE Connectivity, Microsoft, itv|world, Telstra Corporation, and McKinsey & Company. Ms. Dallara has served on the board of directors of Lattice Semiconductor Corporation (Nasdaq: LSCC) since November 2023. Ms. Dallara holds a BSc. in Applied Mathematics (Honours Class 1) and BCom from the University of New South Wales and an MBA from INSEAD in France.- 自2026年3月起，Que Dallara担任MiniMed的首席执行官和董事。2022年5月至2026年3月，Dallara女士担任美敦力糖尿病运营部门执行副总裁兼运营部门总裁。从2018年10月到2022年4月，Dallara女士担任霍尼韦尔 Connected Enterprise的总裁兼首席执行官，该公司是一家多元化的工业集团企业霍尼韦尔国际公司的软件业务。2017年1月至2019年10月，Dallara女士担任霍尼韦尔高级副总裁兼首席商务官。在2017年加入霍尼韦尔之前，Dallara女士曾在泰科电子、微软、ITV | world、Telstra Corporation、麦肯锡公司任职。Dallara女士自2023年11月起担任Lattice Semiconductor Corporation（纳斯达克：LSCC）的董事会成员。Dallara女士拥有新南威尔士大学应用数学（荣誉1级）和BCoM的理学学士学位，以及法国INSEAD的MBA学位。
- Que Dallara has served as Chief Executive Officer and a Director of MiniMed since March 2026. From May 2022 to March 2026, Ms. Dallara served as Executive Vice President and Operating Unit President of the Diabetes Operating Unit of Medtronic. From October 2018 to April 2022, Ms. Dallara served as President and Chief Executive Officer of Honeywell Connected Enterprise, the software business of Honeywell International, Inc., a diversified industrial conglomerate. From January 2017 to October 2019, Ms. Dallara served as Senior Vice President and Chief Commercial Officer of Honeywell. Before joining Honeywell in 2017, Ms. Dallara worked at TE Connectivity, Microsoft, itv|world, Telstra Corporation, and McKinsey & Company. Ms. Dallara has served on the board of directors of Lattice Semiconductor Corporation (Nasdaq: LSCC) since November 2023. Ms. Dallara holds a BSc. in Applied Mathematics (Honours Class 1) and BCom from the University of New South Wales and an MBA from INSEAD in France.
- Gillian Chandrasena
Gillian Chandrasena自2026年3月起担任MiniMed高级副总裁、首席人力资源官。从2025年3月到2026年3月，Chandrasena女士此前曾担任美敦力糖尿病运营部门人力资源副总裁。从2025年2月到2025年3月，Chandrasena女士在美敦力担任产品创新与质量人力资源副总裁。2022年3月至2025年2月，Chandrasena女士在Reliance Worldwide Corporation担任首席人事官。2020年12月至2022年3月，Chandrasena女士在多元化工业集团（霍尼韦尔）旗下的霍尼韦尔国际公司（TERM1）担任霍尼韦尔 Connected Enterprise人力资源副总裁。在加入霍尼韦尔之前，Chandrasena女士曾在Brambles Limited和Centrica担任高级人力资源职务。Chandrasena女士拥有De Montfort大学的学士和MBA学位、泰晤士河谷大学的人力资源研究生文凭以及教练学院的教练认证。
Gillian Chandrasena has served as Senior Vice President, Chief Human Resources Officer of MiniMed since March 2026. From March 2025 to March 2026, Ms. Chandrasena previously served as Vice President, Human Resources of the Diabetes Operating Unit at Medtronic. From February 2025 to March 2025, Ms. Chandrasena served as Vice President, Human Resources of Product Innovation & Quality at Medtronic. From March 2022 to February 2025, Ms. Chandrasena served as Chief People Officer at Reliance Worldwide Corporation. From December 2020 to March 2022, Ms. Chandrasena served as Vice President, Human Resources, of Honeywell Connected Enterprise at Honeywell International Inc., a diversified industrial conglomerate (Nasdaq: HON) ("Honeywell"). Prior to Honeywell, Ms. Chandrasena held senior human resources roles at Brambles Limited and Centrica. Ms. Chandrasena holds a B.A. and an MBA from De Montfort University, a post graduate diploma in Human Resources from Thames Valley University, and a coaching certification from The Coaches Institute.- Gillian Chandrasena自2026年3月起担任MiniMed高级副总裁、首席人力资源官。从2025年3月到2026年3月，Chandrasena女士此前曾担任美敦力糖尿病运营部门人力资源副总裁。从2025年2月到2025年3月，Chandrasena女士在美敦力担任产品创新与质量人力资源副总裁。2022年3月至2025年2月，Chandrasena女士在Reliance Worldwide Corporation担任首席人事官。2020年12月至2022年3月，Chandrasena女士在多元化工业集团（霍尼韦尔）旗下的霍尼韦尔国际公司（TERM1）担任霍尼韦尔 Connected Enterprise人力资源副总裁。在加入霍尼韦尔之前，Chandrasena女士曾在Brambles Limited和Centrica担任高级人力资源职务。Chandrasena女士拥有De Montfort大学的学士和MBA学位、泰晤士河谷大学的人力资源研究生文凭以及教练学院的教练认证。
- Gillian Chandrasena has served as Senior Vice President, Chief Human Resources Officer of MiniMed since March 2026. From March 2025 to March 2026, Ms. Chandrasena previously served as Vice President, Human Resources of the Diabetes Operating Unit at Medtronic. From February 2025 to March 2025, Ms. Chandrasena served as Vice President, Human Resources of Product Innovation & Quality at Medtronic. From March 2022 to February 2025, Ms. Chandrasena served as Chief People Officer at Reliance Worldwide Corporation. From December 2020 to March 2022, Ms. Chandrasena served as Vice President, Human Resources, of Honeywell Connected Enterprise at Honeywell International Inc., a diversified industrial conglomerate (Nasdaq: HON) ("Honeywell"). Prior to Honeywell, Ms. Chandrasena held senior human resources roles at Brambles Limited and Centrica. Ms. Chandrasena holds a B.A. and an MBA from De Montfort University, a post graduate diploma in Human Resources from Thames Valley University, and a coaching certification from The Coaches Institute.